🔎 Trials Near Me

Home › Crohn's Disease › North Carolina

Crohn's Disease clinical trials in North Carolina

20 studies for Crohn's Disease are looking for participants at sites in North Carolina.

Cities in North Carolina

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

  • University of North Carolina Medical Center ( Site 5034), Chapel Hill
  • Atrium Health Gastroenterology MMP ( Site 5105), Charlotte
RecruitingPhase 3
Ages 16 to 80 · All sexes · Updated Oct 2, 2026 · NCT06430801

Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis

  • Digestive Health Partners /ID# 280490, Asheville
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Oct 2, 2026 · NCT07697456

A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting

  • Charlotte Gastroenterology and Hepatology, P.L.L.C, Charlotte
  • Carolina Digestive Diseases, Greenville
  • Piedmont Healthcare, Statesville
  • and 1 more
RecruitingPhase 4
Ages 18 to 80 · All sexes · Updated Sep 30, 2026 · NCT06581328

Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease

  • Digestive Health Partners - Biltmore Office /ID# 265539, Asheville
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 25, 2026 · NCT06548542

A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease

  • University of North Carolina at Chapel Hill, Chapel Hill
  • Charlotte Gastroenterology and Hepatology, PLLC, Charlotte
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07499232

A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease

  • University of North Carolina, Chapel Hill
  • Atrium Health, Charlotte
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07196722

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

  • Coastal Research Institute - Fayetteville, Fayetteville
RecruitingPhase 3
Ages 18 to 70 · All sexes · Updated Sep 24, 2026 · NCT06937099

An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

  • UNC Hospitals, The University of North Carolina at Chapel Hill-Site Number: 8400074, Chapel Hill
  • OnSite Clinical Solutions-Site Number: 8400051, Charlotte
  • Duke University Medical Center-Site Number: 8400093, Durham
  • and 3 more
RecruitingPhase 3
Ages 16 to 80 · All sexes · Updated Sep 23, 2026 · NCT07184931

A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

  • UNC Hospitals, The University of North Carolina at Chapel Hill-Site Number: 8400074, Chapel Hill
  • Cross Creek Medical Clinic-Site Number: 8400057, Fayetteville
RecruitingPhase 3
Ages 16 to 80 · All sexes · Updated Sep 23, 2026 · NCT07184944

A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease

  • Cross Creek Medical Clinic, Fayetteville
  • Peters Medical Research, High Point
  • Wake Research Associates, Raleigh
RecruitingPhase 2
Ages 18 to 85 · All sexes · Updated Sep 22, 2026 · NCT06226883

A Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically

  • University of North Carolina at Chapel Hill, Chapel Hill
RecruitingPhase 4
Ages 18 and older · Women · Updated Aug 28, 2026 · NCT07654751

A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease

  • University of North Carolina Hospital, Chapel Hill
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 28, 2026 · NCT07577843

Zymfentra (Infliximab-dyyb) REal World Cohort STudy

  • University of North Carolina, Chapel Hill
  • Atrium Health Center for Gastroenterology and Surgery, Charlotte
  • Wake Forest School of Medicine, Winston-Salem
RecruitingObservational study
Ages 18 and older · All sexes · Updated Aug 5, 2026 · NCT07237516

Comparing Over the Counter Pain Medicines for Discomfort in Crohn's Disease (AVID-CD)

  • University of North Carolina at Chapel Hill, Chapel Hill
Recruiting
Ages 18 to 44 · Women · Updated Jul 14, 2026 · NCT07337902

Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease

  • Univ NC Chapel Hill /ID# 262198, Chapel Hill
RecruitingPhase 3
Ages 2 to 17 · All sexes · Updated Jun 24, 2026 · NCT06332534

Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease

  • Levine Children's, Charlotte
RecruitingPhase 4
Ages 6 to 17 · All sexes · Updated May 27, 2026 · NCT05781152

COMPARE - Pediatric Inflammatory Bowel Disease (PIBD)

  • University of North Carolina at Chapel Hill, Chapel Hill
  • Atrium Health, Charlotte
  • Duke Health System, Durham
RecruitingObservational study
Ages 1 to 18 · All sexes · Updated Apr 17, 2026 · NCT07198113

A Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease

  • Investigational Site Number: 8400003, Chapel Hill
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Mar 27, 2026 · NCT06958536

A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease

  • Mirador Therapeutics Selected Site, High Point
  • Mirador Therapeutics Selected Site, Raleigh
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Mar 12, 2026 · NCT07113522

Study to Evaluate Pregnancy Outcomes in Risankizumab Exposed Pregnancies Relative to Those Non-risankizumab Exposed Pregnancies in Women With FDA Approved Indications

  • Evidera, a PPD Business Unit /ID# 238688, Morrisville
RecruitingObservational study
All ages · Women · Updated Jul 17, 2025 · NCT04846959

From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.